Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis

Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study

(2015) A. Ogata et al.   JOURNAL OF RHEUMATOLOGY

Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis

(2015) Atsushi Ogata et al.   ARTHRITIS CARE & RESEARCH

Emerging role of leptin in rheumatoid arthritis

(2014) G. Tian et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis

(2014) Alan Kivitz et al.   ARTHRITIS CARE & RESEARCH

A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)

(2013) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study)

(2013) Shuji Ohta et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan

(2013) T. Koike et al.   JOURNAL OF RHEUMATOLOGY

Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis

(2013) Atsushi Ogata et al.   ARTHRITIS CARE & RESEARCH

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

(2012) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine

(2012) Elisa Gremese et al.   ARTHRITIS CARE & RESEARCH

2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) D. Aletaha et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

(2010) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Body mass index and clinical response to infliximab in rheumatoid arthritis

(2010) Ruth Klaasen et al.   ARTHRITIS AND RHEUMATISM

Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy

(2010) Jennifer Barton   Patient Preference and Adherence

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD